

November 24, 2015



# Stellar Biotechnologies to Present at LD Micro Main Event

PORT HUENEME, CA -- (Marketwired) -- 11/24/15 -- **Stellar Biotechnologies, Inc.** ("**Stellar**" or "**the Company**") (NASDAQ: SBOT) (TSX VENTURE: KLH), the leader in sustainable manufacture of Keyhole Limpet Hemocyanin ("KLH"), today announced that Frank Oakes, President and Chief Executive Officer of Stellar, will present at the LD Micro Main Event, to be held December 1-3, 2015 in Los Angeles, CA.

During the presentation, Stellar executives will provide a review of recent activities, including the Company's uplisting onto the Nasdaq Capital Market. Full details of the presentation follow:

## **Stellar Biotechnologies Presentation Details**

**Date:** Wednesday, December 2, 2015

**Time:** 1:30-2:00 PM PT (4:30-5:00 PM ET) in Track 3

**Location:** Luxe Sunset Boulevard Hotel, Los Angeles, CA

Stellar's presentation will be webcast live at: <http://www.wsw.com/webcast/ldmicro9/sbot> The presentation will also be available after the conference on the Company's website at: <http://ir.stellarbiotechnologies.com/events-calendar>

Stellar senior management will also be available during the conference for one-on-one meetings. Members of the investment community who are interested in meeting with the Company should contact LD Micro Conference coordinators to arrange an appointment.

For more information regarding the LD Micro Main Event visit:

<http://www.ldmicro.com/p/main-event.html>

## **About Stellar Biotechnologies, Inc.**

*Stellar Biotechnologies, Inc. (NASDAQ: SBOT) (TSX VENTURE: KLH) is the leader in sustainable manufacture of Keyhole Limpet Hemocyanin (KLH), an important immune-stimulating protein used in wide-ranging therapeutic and diagnostic markets. KLH is both an active pharmaceutical ingredient (API) in many new immunotherapies (targeting cancer, immune disorders, Alzheimer's and inflammatory diseases) as well as a finished product for measuring immune status. Stellar Biotechnologies is unique in its proprietary methods, facilities, and KLH technology. We are committed to meeting the growing demand for commercial-scale supplies of GMP grade KLH, ensuring environmentally sound KLH production, and developing KLH-based active immunotherapies.*

Visit [www.stellarbiotech.com](http://www.stellarbiotech.com) and the KLH knowledge base [www.klbsite.org](http://www.klbsite.org).

## *Forward Looking Statements*

*This press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements may be identified by the use of words such as "anticipate," "believe," "plan," "estimate," "expect," "intend," "may," "will," "would," "could," "should," "might," "potential," or "continue" and variations or similar expressions. Readers should not unduly rely on these forward-looking statements, which are not a guarantee of future performance. There can be no assurance that forward-looking statements will prove to be accurate, as all such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause actual results or future events to differ materially from the forward-looking statements. Such risks include, but may not be limited to: general economic and business conditions; technology changes; competition; changes in strategy or development plans; governmental regulations and the ability or failure to comply with governmental regulations; the timing of anticipated results; and other factors referenced in the Company's filings with securities regulators. For a discussion of further risks and uncertainties related to the Company's business, please refer to the Company's public company reports filed with the TSX Venture Exchange and the U.S. Securities and Exchange Commission. All forward-looking statements are made as of the date hereof and are subject to change. Except as required by law, the Company assumes no obligation to update such statements. This press release does not constitute an offer or solicitation of an offer for sale of any securities in any jurisdiction, including the United States. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of the information contained in this press release.*

### ***Stellar Biotechnologies Company Contact:***

Mark A. McPartland

Vice President of Corporate Development and Communications

Phone: +1 (805) 488-2800 ext. 103

[markmcp@stellarbiotech.com](mailto:markmcp@stellarbiotech.com)

[www.stellarbiotech.com](http://www.stellarbiotech.com)

### ***Investor Inquiries:***

Joseph Green

The Ruth Group

Phone: +1 (646) 536-7013

[jgreen@theruthgroup.com](mailto:jgreen@theruthgroup.com)

### ***Media Inquiries:***

Joanna Zimmerman

The Ruth Group

Phone: +1 (646) 536-7006

[jzimmerman@theruthgroup.com](mailto:jzimmerman@theruthgroup.com)

Source: Stellar Biotechnologies, Inc.